Literature DB >> 28154951

Reply to comments from Vincent et al.

Kazuo Tamura1.   

Abstract

Year:  2017        PMID： 28154951     DOI： 10.1007/s10147-017-1093-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  5 in total

Review 1.  Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.

Authors:  Mitchell S Cairo; Bertrand Coiffier; Alfred Reiter; Anas Younes
Journal:  Br J Haematol       Date:  2010-03-16       Impact factor: 6.998

2.  Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.

Authors:  Michael D Mayer; Reza Khosravan; Laurent Vernillet; Jing-Tao Wu; Nancy Joseph-Ridge; Darcy J Mulford
Journal:  Am J Ther       Date:  2005 Jan-Feb       Impact factor: 2.688

3.  Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology.

Authors:  Gail L Jones; Andrew Will; Graham H Jackson; Nicholas J A Webb; Simon Rule
Journal:  Br J Haematol       Date:  2015-04-15       Impact factor: 6.998

4.  Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment.

Authors:  Daiki Hira; Yugo Chisaki; Satoshi Noda; Hisazumi Araki; Takashi Uzu; Hiroshi Maegawa; Yoshitaka Yano; Shin-Ya Morita; Tomohiro Terada
Journal:  Pharmacology       Date:  2015-07-11       Impact factor: 2.547

5.  Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.

Authors:  Kazuo Tamura; Yasukazu Kawai; Toru Kiguchi; Masataka Okamoto; Masahiko Kaneko; Makoto Maemondo; Kenichi Gemba; Katsumichi Fujimaki; Keita Kirito; Tetsuya Goto; Tomoaki Fujisaki; Kenji Takeda; Akihiro Nakajima; Takanori Ueda
Journal:  Int J Clin Oncol       Date:  2016-03-26       Impact factor: 3.402
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.